首页> 外文期刊>Drug research >Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy Chinese male volunteers
【24h】

Pharmacokinetics and bioequivalence of two ibuprofen sustained-release formulations after single and multiple doses in healthy Chinese male volunteers

机译:两种布洛芬缓释制剂在中国男性健康志愿者中一次和多次给药后的药代动力学和生物等效性

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives: The aim of this study was to compare the bioavailability of 2 ibuprofen sustained-release formulations after single and multiple doses. Methods: It was conducted on 19 healthy Chinese male volunteers according to an open, randomized, single-blind, 2-way crossover study. Plasma concentrations were determined by liquid chromatography-mass spectrometry. Pharmacokinetic parameters were calculated using a non-compartment model. Results: In the single-dose study, the values of Cmax, tmax, t 1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 12.59±2.29 and 12.84±2.79 μg/mL, 4.5±1.1 and 4.3±0.7 h, 4.15±1.37 and 4.03±0.86 h, 83.71±21.01 and 86.32±23.42 μg · h/mL, 86.05±21.37 and 88.99±25.33 μg · h/mL, respectively. In the multiple-dose study, the values of Cmax, Cmin, t max, t1/2, AUCss, DF for test and reference formulations were 14.46±3.08 and 14.00±2.61 μg/mL, 0.47±0.21 and 0.63±0.45 μg/mL, 4.0±0.9 and 4.3±0.9 h, 4.69±1.61 and 4.99±2.16 h, 89.11±19.04 and 89.23±20.56 μg · h/mL, 3.25±0.50 and 3.06±0.71, respectively. Single-dose relative bioavailability were 97.8±10.5% for AUC0-τ and multiple-dose relative bioavailability were 100.6±9.4% for AUCss. The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80-125%. Conclusions: This means that the test formulation is bioequivalent to the reference formulation.
机译:目的:本研究的目的是比较单次和多次给药后2种布洛芬缓释制剂的生物利用度。方法:根据一项开放,随机,单盲,两向交叉研究,对19位健康的中国男性志愿者进行了这项研究。通过液相色谱-质谱法测定血浆浓度。使用非房室模型计算药代动力学参数。结果:在单剂量研究中,测试和参考制剂的Cmax,tmax,t 1/2,AUC0-τ,AUC0-∞值为12.59±2.29和12.84±2.79μg/ mL,4.5±1.1和4.3分别为±0.7 h,4.15±1.37和4.03±0.86 h,83.71±21.01和86.32±23.42μg·h / mL,86.05±21.37和88.99±25.33μg·h / mL。在多剂量研究中,测试和参考制剂的Cmax,Cmin,tmax,t1 / 2,AUCss,DF值分别为14.46±3.08和14.00±2.61μg/ mL,0.47±0.21和0.63±0.45μg/ mL mL,4.0±0.9和4.3±0.9 h,4.69±1.61和4.99±2.16 h,89.11±19.04和89.23±20.56μg·h / mL,3.25±0.50和3.06±0.71。 AUC0-τ的单剂量相对生物利用度为97.8±10.5%,而AUCss的多剂量相对生物利用度为100.6±9.4%。对数转换数据的T / R比率的90%置信区间在普遍接受的80-125%范围内。结论:这意味着测试制剂与参考制剂具有生物等效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号